A Multicenter, Randomized, Controlled Trial to Evaluate the Effectiveness and Safety of Systemic Corticosteroid Treatment for Hospitalized Patients With Severe Acute Respiratory Infection and Hypoxemia (STRIVE 003)
National Institute of Allergy and Infectious Diseases (NIAID)
Summary
Multicenter, parallel-group, randomized clinical trial comparing the administration of systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days vs no corticosteroid administration among adults hospitalized with severe acute respiratory infection and hypoxemia.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age ≥ 18 years. * Severe acute respiratory infection (SARI), defined as a suspected infection of the respiratory tract that meets each of the following 4 criteria: 1. Onset in the last 10 days AND 2. Results in hospitalization AND 3. At least one symptom or sign of respiratory illness (defined as purulent sputum, new or worsened cough, new or worsened dyspnea, tachypnea with respiratory rate ≥22 breaths per minute, rales, or bronchial breath sounds) AND 4. At least one symptom or sign of acute infection (defined as a temperature ≥38°C or ≤36°C, feverishness, chi…
Interventions
- DrugCorticosteroid
systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days or until discharge
Location
- University of MinnesotaMinneapolis, Minnesota